Every IVF Patient Is Already on Peptides
Lupron, Ganirelix, hCG, Omnitrope — the standard IVF protocol is a peptide protocol. The only difference between "fertility medicine" and "research peptides" is who's selling them.
Kisspeptin Trigger
vs 7% with hCG
📋 On this page
- IVF Drugs Are Peptides
- The Regulatory Double Standard
- TRT → Infertility → Peptides
- Kisspeptin: 42 Babies, Zero OHSS
- Growth Hormone in IVF
- GLP-1 Agonists & Fertility
- The hCG Compounding Ban
- Investigational Peptides & Fertility
- Pharmacogenomics & Fertility Response
- Peptides & Fertility: A Timeline
- Key Takeaways
- OTC Fertility Supplements
- Related Research Guides
IVF Drugs Are Peptides
Walk into any fertility clinic in America and you'll get a protocol sheet full of peptides. They just don't call them that. Here's what's actually in the IVF drug cabinet — and what the same molecules are called outside of it.
| Brand Name | Generic / Molecule | Class | IVF Use | Status |
|---|---|---|---|---|
| Lupron | Leuprorelin (leuprolide) | GnRH agonist peptide | Pituitary downregulation | Same molecule |
| Ganirelix | Ganirelix acetate | GnRH antagonist peptide | Premature ovulation prevention | Same molecule |
| Gonal-F | Follitropin alfa | Recombinant glycoprotein hormone | Ovarian stimulation | Same molecule |
| Pregnyl / Ovidrel | hCG (human chorionic gonadotropin) | Peptide hormone | Ovulation trigger | Same molecule |
| Omnitrope | Somatropin (growth hormone) | 191-amino acid peptide | Adjunct for poor responders | Same molecule |
The punchline: Every molecule in the "IVF drugs" column exists as a "research peptide" with identical amino acid sequences. The FDA approves them in one context and treats them as unregulated in another. The molecule doesn't change — only the label does.
The Regulatory Double Standard
Same molecules. Same amino acid sequences. Same mechanism of action. Different rules. The line between "approved fertility drug" and "research chemical" isn't drawn by science — it's drawn by commerce.
In a Fertility Clinic
GnRH analogues are "FDA-approved medications." Prescribed daily. Covered by some insurance. Administered by nurses. Published in NEJM.
Outside a Fertility Clinic
The same GnRH analogues are "research chemicals — not for human consumption." Sold by peptide vendors. Discussed on forums. Viewed with suspicion.
📋 Patent Expiry
Many fertility peptides are off-patent. Generic competition drives prices down — but also removes the financial incentive for pharma to maintain broad accessibility.
⚖️ Classification Games
The BPCIA (2020) reclassified hCG as a biologic, eliminating compounding access. Same molecule, new rules, 5-7x price increase overnight.
🌍 Global Inconsistency
Kisspeptin is an active IVF trigger in UK clinical trials but has no FDA pathway in the US. Same molecule, same data, different continents, different rules.
💰 Follow the Money
FDA-approved fertility drugs generate $7B+ annually. "Research peptides" with identical sequences threaten that revenue model. Regulation follows incentives.
TRT → Infertility → Peptides
Eleven million Americans are on testosterone replacement therapy. Exogenous testosterone suppresses the HPG axis, shutting down natural sperm production. The result: an ever-growing pipeline of men who need fertility interventions — interventions that are themselves peptide-based.
11M TRT Scripts
Testosterone prescribed for low-T symptoms
Suppressed HPG
FSH/LH crash, sperm production stops
Fertility Crisis
Azoospermia, need for IVF/ICSI
Peptide Rescue
hCG, GnRH analogues, enclomiphene
The circular economy of fertility: TRT creates the problem. Peptides solve it. The same patients who might have used peptides (enclomiphene, gonadorelin) to avoid TRT-induced infertility in the first place end up needing different peptides (hCG, GnRH agonists) to reverse it. The molecules could have prevented the problem they're now being used to treat.
TRT Impact on Sperm Parameters
Kisspeptin: 42 Babies, Zero OHSS
Ovarian hyperstimulation syndrome (OHSS) is the most dangerous complication of IVF. It hospitalizes thousands annually and can be fatal. Kisspeptin — a naturally occurring neuropeptide — may eliminate it entirely.
🎯 Dhillo Trial — NCT01667406
42 healthy babies born. 0% OHSS rate. 62% live birth rate at the optimal 9.6 nmol/kg dose. Standard hCG trigger: ~7% OHSS.
👃 Intranasal Kisspeptin
Lancet eBioMedicine (April 2025) published data on intranasal delivery. Non-injectable, patient-friendly, same GnRH-triggering mechanism.
💊 MVT-602
Kisspeptin analogue with longer half-life. Fertility & Sterility (Jan 2024) published Phase 2a results for assisted reproduction applications.
🧠 How It Works
Kisspeptin triggers endogenous GnRH release → natural LH surge → oocyte maturation. Unlike hCG, the signal is self-limiting, preventing the sustained stimulation that causes OHSS.
OHSS Rate: Kisspeptin vs hCG Trigger
The most critical safety comparison in modern IVF
Live Birth Rate by Kisspeptin Dose
Phase 2 data — dose-response relationship
Data from Dhillo et al., Phase 2 (NCT01667406). Dose-response is illustrative based on published optimal dose findings.
Growth Hormone in IVF
Growth hormone (somatropin) is widely used as an IVF adjunct for "poor responders." But the evidence is a battlefield. Depending on which study you read, GH either meaningfully improves outcomes or does absolutely nothing.
The Case For
2025 umbrella review of meta-analyses found OR 1.80 for live birth with GH co-treatment. Multiple meta-analyses show improved oocyte yield and embryo quality in poor responders.
The Case Against
Mourad 2025 (Human Reproduction): GH in IVF provides no meaningful benefit. The LIGHT study — the largest RCT to date — was stopped for futility. Publication bias suspected.
GH + IVF Evidence Strength
How the evidence stacks up
The pattern: Meta-analyses of small, heterogeneous studies show benefit. Large, well-designed RCTs show none. This is the classic publication bias signature — small positive studies get published, small negative ones don't. Until another large RCT confirms or denies, GH in IVF remains a $2,000/cycle bet on contested evidence.
GLP-1 Agonists & Fertility
Semaglutide (Ozempic/Wegovy) isn't a fertility drug — but its dramatic weight loss effects are reshaping fertility outcomes for women with PCOS. The catch: you have to stop it before getting pregnant.
🔄 PCOS + Weight Loss
PCOS is the #1 cause of anovulatory infertility. GLP-1-driven weight loss (15-20% body weight) restores ovulation in many PCOS patients who failed other interventions.
🧬 Insulin Sensitivity
GLP-1 agonists improve insulin resistance — the metabolic driver behind PCOS. Better insulin = lower androgens = restored ovulatory cycles.
⏱️ The 2-Month Washout
Current guidance: discontinue semaglutide at least 2 months before attempting conception. Limited data on fetal exposure. This is non-negotiable.
👶 "Ozempic Babies"
Anecdotal reports of unexpected pregnancies after starting GLP-1s — weight loss restoring fertility faster than expected. Not evidence, but the pattern is consistent.
⚠️ Critical safety note: GLP-1 receptor agonists are NOT approved for fertility use. The 2-month washout before conception is based on the drug's half-life and limited reproductive toxicity data. Never use during pregnancy or while actively trying to conceive without explicit medical guidance.
The hCG Compounding Ban
In 2020, the FDA reclassified hCG as a biologic under the Biologics Price Competition and Innovation Act (BPCIA). Overnight, compounding pharmacies lost the ability to make affordable hCG. The impact was immediate and devastating.
5-7×
Price increase for hCG after reclassification. What cost $50-80 now costs $300-500+.
5/75
Pharmacies still carrying hCG post-ban. Only 6.7% of surveyed pharmacies maintained stock.
2020
Year of reclassification. BPCIA moved hCG from drug to biologic classification.
Who gets hurt: TRT patients who relied on compounded hCG to maintain fertility. IVF patients facing dramatically higher costs. Male hypogonadism patients who used low-dose hCG for HPG axis preservation. The FDA's stated goal was safety — but the practical result was reduced access and increased cost for the same molecule that had been safely compounded for decades.
Investigational Peptides & Fertility
⚠️ IMPORTANT DISCLAIMER: The following peptides have NO human fertility trial data. All evidence is from animal models or in-vitro studies. This section exists for scientific completeness, not to suggest clinical use. Do not use these compounds for fertility purposes.
BPC-157
Body Protection Compound-157 has shown tissue-repair properties in animal models across multiple organ systems. Theoretical applications to reproductive tissue repair exist in the literature, but no fertility-specific studies have been conducted. All claims about fertility benefits are speculative extrapolation.
TB-500 (Thymosin Beta-4)
Thymosin β4 expression has been documented in cumulus cells surrounding oocytes and in spermatogonia (sperm precursor cells). This suggests a natural role in reproductive biology — but documenting expression is very different from proving therapeutic benefit. No human fertility data exists.
Expression ≠ therapeutic target. Many proteins are expressed in reproductive tissues without being viable drug targets. These are areas of basic research interest, not actionable clinical data.
Pharmacogenomics & Fertility Response
Why does the same IVF protocol work brilliantly for one patient and fail completely for another? Increasingly, the answer is pharmacogenomics — genetic variants that affect how your body processes fertility drugs.
| Gene / Variant | What It Affects | Clinical Impact |
|---|---|---|
| FSHR polymorphisms | FSH receptor sensitivity | Ser680Asn variant → 30-50% higher FSH doses needed. Explains "poor responders" who need more gonadotropins for the same ovarian response. |
| GHR variants | Growth hormone receptor | GHR d3 deletion variant → enhanced GH sensitivity. May explain why some patients respond to GH adjunct therapy and others don't. |
| CYP19A1 (aromatase) | Estrogen synthesis from androgens | Polymorphisms affect letrozole/clomiphene response. Variant carriers may need dose adjustments for ovulation induction. |
| LHCGR variants | LH/hCG receptor binding | Affects hCG trigger efficacy and luteal phase support. May partially explain variable OHSS risk between patients. |
| CYP enzymes (2D6, 3A4) | Drug metabolism speed | Ultra-rapid metabolizers clear drugs faster, potentially needing higher doses. Poor metabolizers accumulate drug, increasing side effect risk. |
The future: Pharmacogenomic testing before IVF could personalize protocols — right drug, right dose, first cycle. Some clinics are already testing FSHR variants. Within 5 years, pre-IVF genetic panels may become standard of care.
Peptides & Fertility: A Timeline
From the discovery of GnRH to intranasal kisspeptin — 55 years of reproductive peptide science.
Key Takeaways
✅ What We Know
- Every standard IVF protocol uses peptides — Lupron, Ganirelix, hCG, FSH are all peptide-based
- Kisspeptin trigger: 62% live birth rate, 0% OHSS in Phase 2 trials (Dhillo)
- TRT (11M scripts/year) suppresses sperm → creates demand for fertility peptides
- hCG compounding ban (2020) caused 5-7× price increase, 93% pharmacy dropout
- GLP-1 weight loss improves PCOS-related infertility (with 2-month washout required)
- FSHR pharmacogenomics can explain "poor responder" status in IVF
⚠️ What We Don't
- Kisspeptin has no FDA approval yet — Phase 3 data still pending
- Growth hormone in IVF: meta-analyses vs RCTs disagree; LIGHT study stopped for futility
- GLP-1 fertility effects are indirect (weight loss) and safety during pregnancy is unestablished
- BPC-157 and TB-500 have zero human fertility data — all evidence is preclinical
- Pharmacogenomic testing for IVF is promising but not yet standard of care
- Long-term effects of the hCG compounding ban on fertility outcomes are still being measured
OTC Fertility Supplements
Evidence-supported supplements commonly used alongside fertility treatments. These are over-the-counter products — not replacements for medical care.
Research Peptides & Compounds
Looking for research-grade peptides including GnRH analogues, BPC-157, TB-500, and more? Swiss Chems offers third-party tested products for research purposes.
Browse Swiss Chems →Related Research Guides
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →Educational content only. Not medical advice. This page is for informational and research purposes only. The peptides and compounds discussed include FDA-approved fertility medications, investigational drugs in clinical trials, and research compounds without human data. Nothing on this page should be interpreted as a recommendation for self-treatment. Fertility treatment requires professional medical supervision. Some compounds mentioned (BPC-157, TB-500) are sold for research purposes only and are not approved for human use. Always consult with a qualified reproductive endocrinologist or fertility specialist before starting any treatment protocol. Clinical trial identifiers (NCT numbers) are provided for verification — look them up at clinicaltrials.gov.